Member Info for Fredd1eboy

Hi mannar. Any idea who william henry salomon is & if so , his relationship/interest in Oxford Biodyn.....over and above today's disclosure. Sincerely Fred

.. below 0.5p... bodes well....

Topped up a tad under 0.5p...

Excellent strategy warrie... I plan to follow suit

We're up 2.5%....let's hope common sense now continues to win over speculation...

.. plenty of buys... 👍

Looking good and last trade for 2M ... 👍

Thanks for dosing me with a sprinkling of oxalic acid ant....the future is looking brighter by the minute. Good luck and best regards my friend.

Https://www.youtube.com/watch?v=sVL5-Jz5Ibo

Ive just watched this twice and found it very informative. Lots I guess you already know but I felt it exceptionally educational.........albeit my tiny brain can only handle so much...points of interest ref SRNA and RNA based therapies.....versatility of the payload that can be deilvered....also the delivery of toxic payloads where if left in the body would do ireparable damage. So the delivery of the payload goes to exactly where its required and then inactivated, also the residiual poison harmlessly ejected from the body....Theres so much more content, especially with regard to a a liver fibrosed case study....Will read again as, being a non scientifically investor more to sink in.

https://www.youtube.com/watch?v=sVL5-Jz5Ibo

Hi All....A nice £10k buy just landed.....sign of things to come...

...traded and 1.25% wiped off the value of the company. .......that's the way to look at the antics of the market manipulators ...A joke. .......as soon as quantified £.. news drops.....a true'sh. valuation will be revealed... In the meantime....my advice to myself is to buy on the dips......but dont take my word for it.....please DYOR ..

Patience...Olearney....good things come to those who wait....

Too true CB....Thse days Aptamer-Group is taking my attention.....Val just upsets me.

Great post Takayama.....really positive and fully agreed. Best regards Fred

....looks like the markets been trump'd ....In my humble opinion we are the bargain of a life time....dyor & patience required....as simple as that....as news will come....and I'm expecting a string of good news.... ps. .I topped up this morning. My trade is booked as a sell....

Nice 2,048,758 Buy* £8,994

It seems like you're referring to "aptamers." Aptamers are short, single-stranded DNA or RNA molecules that can bind to specific target molecules with high affinity and specificity. They are often compared to antibodies in their ability to recognize and bind to targets, but they are synthesized in vitro and have some unique advantages, such as stability and ease of modification.

### Key Points About Aptamers:

1. **Applications**:

- **Diagnostics**: Aptamers are used in biosensors and diagnostic assays to detect proteins, small molecules, and pathogens.

- **Therapeutics**: They can be developed as drugs to target specific proteins or cells, such as in cancer therapy.

- **Research Tools**: Aptamers are used in molecular biology to study protein function and interactions.

2. **Advantages**:

- High specificity and affinity for their targets.

- Can be chemically synthesized and modified.

- Stable under a wide range of conditions (e.g., temperature, pH).

3. **Examples**:

- **Pegaptanib (Macugen)**: An FDA-approved aptamer used to treat age-related macular degeneration.

- **AS1411**: An aptamer in clinical trials for cancer treatment.

If you were referring to something else (e.g., a company or product named "Aptimers"), please provide more context, and I’ll do my best to assist!

....Here we come.... much to share guys....I'm sure there will be plenty of interest and further business opportunities. Keep in touch....an inspired investor..

BUYS

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces that it has issued 3,499,343 new ordinary shares of 0.1 pence each ("Ordinary Shares") at an average issue price of 0.2858 pence per Ordinary Share to settle Non-Executive Director fees.